Partnerships, Licensing, Investments and M&A Deals and Trends for September 2019 in Pharmaceuticals

GlobalData
99 Pages - GLDATA68898
$1,000.00

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for September 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry.

The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

'

Table of Contents
1.1. List of Tables 5
1.2. List of Figures 7
2. Deal Values in Pharmaceutical and Healthcare Industry Has Increased in September 2019 9
2.1. Pharmaceuticals & Healthcare, Deals Summary, September 2019 9
3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13
3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2019 13
3.2. Pharmaceuticals & Healthcare, Global, Major Deals, September 2019 14
3.2.1. Thermo Fisher Scientific Raises USD5.7 Billion in Public Offering of Senior Notes 15
3.2.2. China Biologic Products Receives Non-Binding Acquisition Proposal from Buyer Group 15
3.2.3. Sumitomo Dainippon Pharma to Acquire 10% Stake in Roivant Sciences for USD3 Billion 15
3.2.4. Lundbeck to Acquire Alder BioPharma 16
3.2.5. Hansoh Pharma and Atomwise Enter into AI Drug Discovery Agreement 17
3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2019 18
3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2019 19
4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
4.1. Pharmaceuticals & Healthcare, Global, M&A, September 2019 20
4.1.1. Top M&A Deals in September 2019 21
4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2019 - September 2019 22
4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2019 23
4.2.1. Top Equity Offering Deals in September 2019 24
4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2019 - September 2019 25
4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2019 27
4.3.1. Top PE/VC Deals in September 2019 28
4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2019 29
4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2019 30
4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2019-September 2019 32
4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2019-September 2019 33
4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2019 34
4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2019 - September 2019 35
4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2019 37
4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2019 38
4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 39
4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2019 - September 2019 41
4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2019 - September 2019 42
4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 43
5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2019 45
5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2019 45
5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2019 47
5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2019 - September 2019 49
5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2019 - September 2019 51
5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2019 - September 2019 53
5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2019 - September 2019 56
5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2019 57
5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2019 58
5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2019 59
6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 60
6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2019 60
6.1.1. Oncology - Deals of the Month 61
6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2019 63
6.2.1. Central Nervous System - Deals of the Month 64
6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2019 66
6.3.1. Infectious Diseases - Deals of the Month 67
6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2019 70
6.4.1. Cardiovascular - Deals of the Month 71
6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2019 72
6.5.1. Immunology - Deal of the Month 73
6.6. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, September 2019 75
6.6.1. Gastrointestinal - Deals of the Month 76
6.7. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2019 77
6.7.1. Metabolic Disorders - Deals of the Month 78
7. Deal Summary by Geography 80
7.1. Pharmaceuticals & Healthcare, North America Deals, September 2019 80
7.1.1. North America - Deals of the Month 81
7.2. Pharmaceuticals & Healthcare, Europe, Deals, September 2019 83
7.2.1. Europe - Deals of the Month 84
7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2019 86
7.3.1. Asia-Pacific - Deals of the Month 87
7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2019 88
7.4.1. Rest of the World - Deals of the Month 89
8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 91
8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2019 - September 2019 91
8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2019 - September 2019 93
9. Further Information 95
9.1. Methodology 95
9.2. About GlobalData 96
9.3. Contact Us 96
9.4. Disclosure information 96
9.5. Disclaimer 96

List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 14
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, September 2019 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2019 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2019 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2019 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2019 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2019 - September 2019 29
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2019 31
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 32
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2019 - September 2019 33
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 34
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 36
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 37
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2019 38
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 40
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019 42
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2019 - September 2019 44
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 46
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 48
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 50
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2019 52
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019 55
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2019 57
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, September 2019 57
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2019 58
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2019 59
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 61
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 64
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 67
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 71
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 73
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 76
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 78
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 81
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 84
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 87
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 89
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 92
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 94

List of Figures
Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, September 2019 9
Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, April 2019 - September 2019 10
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, September 2019 11
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, September 2019 12
Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 13
Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), September 2019 18
Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), September 2019 19
Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 20
Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019 22
Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 23
Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 25
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 27
Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019 29
Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), September 2019 30
Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), September 2019 31
Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 32
Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 34
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 35
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 37
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 39
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019 41
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019 42
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 43
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 45
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 47
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 49
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019 51
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, April 2019 - September 2019 53
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), April 2019 - September 2019 54
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2019 56
Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 60
Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 63
Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 66
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 70
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 72
Figure 36: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 75
Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 77
Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 80
Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 83
Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 86
Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 88
Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 91
Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2019 - September 2019 93

$1,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports